During Eastern Economic Forum the Pharmasyntez Group of Companies and the Government of Primorsky Krai entered into a cooperation agreement aimed at supporting investment project for creating the first import substitution production in Russia for parenteral (intravenous) nutrition from vital and essential drugs list and anesthetic drugs for intravenous administration with INN Propofol.

The total investment of the Pharmasyntez Group of Companies in the new production will amount to 750 million rubles. The construction of a new facility will be started this year on the basis of EAST-PHARM pharmaceutical plant in Ussuriysk. Commissioning is planned for the third quarter of 2023. 

“Production of parenteral nutrition is a unique and socially significant project, that aims at helping people in a coma or in acute post-surgery period, cancer patients – all those who cannot eat on their own. Currently Russia imports such products, and we have a chance to become the first domestic manufacturer of parenteral nutrition, reduce prices in the domestic market and meet the needs of medical institutions not only in the Far East, but other regions of Russia as well. Pilot batches have already been produced, the first products (amino acids and emulsions) are being registered,” Yury Skachko, Chief Executive Officer of EAST-PHARM LLC, noted.